drugset / Trial / NCT00405873
Study to Evaluate Tumour Response in Cancer Patients With Advanced Hepatocellular Carcinoma (Liver Cancer) With AMT2003
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate the efficacy and the safety of AMT2003 in cancer patients with advanced primary hepatocellular carcinoma The primary endpoint is best overall response rate within 20 weeks after registration
Timeline
- Start
- 2007-03
- Primary completion
- 2010-03
- Completion
- 2010-03
Outcome
Outcome not reported
Stopped: “Lack of efficacy”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AMT2003 | Unknown | — | — |